Thu, Oct 30, 2014, 2:22 PM EDT - U.S. Markets close in 1 hr 38 mins

Recent

% | $
Quotes you view appear here for quick access.

Seattle Genetics Inc. Message Board

  • richardryan40 richardryan40 Mar 27, 2012 3:09 AM Flag

    2012 ADCETRIS Calendar

    ADCETRIS is being evaluated in:
    1. A phase III clinical trial (the AETHERA trial) for patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant (ASCT)
    2. A phase II trial for relapsed or refractory CD30-positive non-Hodgkin lymphomas
    3. A phase II trial for CD30-positive non-lymphoma malignancies
    4. A phase II retreatment trial for relapsed patients who previously responded to ADCETRIS
    5. A phase I trial in combination with multi-agent chemotherapy for front-line treatment of Hodgkin lymphoma
    6. A phase I trial in combination with multi-agent chemotherapy for front-line treatment of mature T-cell lymphomas. 7.A trial in CD30-positive cutaneous T-cell lymphomas to begin in mid-2012
    8. A front-line trial in Hodgkin lymphoma to begin by late 2012 or early 2013
    9. A front-line trial in mature T-cell lymphomas. to begin by late 2012 or early 2013

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
SGEN
35.60+0.33(+0.94%)2:21 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.